Treatment of Primary CNS Lymphoma in HIV Infection with Severe Immunosuppression
Primary central nervous system lymphoma (PCNSL) arising in the setting of HIV infection with severe immunosuppression presents a distinct clinical challenge, as the treatment approach must account for the underlying immune deficiency alongside the lymphoma itself.
Clinical Scenario
PCNSL occurs generally in HIV patients with severe immunosuppression. This immune context directly influences treatment eligibility, agent selection, and the coordination of care required across specialties.
Treatment Approach — Partial Overview
The approach combines antiretroviral therapy — initiated or modified in coordination with an infectious disease specialist — with systemic HD-MTX-based chemotherapy; polychemotherapy is preferred over single-agent regimens in eligible patients.
Eligibility criteria, regimen selection, and alternative pathways for patients who cannot receive HD-MTX-based treatment are covered in the full protocol →
References
DOI: 10.1093/neuonc/noac196
- PCNSL occurs generally in HIV patients with severe immunosuppression.
- Initiation, if not yet done, or modification of ART should be done in conjunction with the infectious disease specialist (Good Practice Point).
- Patients with adequate performance status (arbitrarily defined as KPS≥60) and able to tolerate it (adequate renal function, absence of pleural or abdominal effusion) should be offered treatment with HD-MTX based chemotherapy.
- Polychemotherapy should be preferred to MTX monotherapy (Good Practice Point).
View source ↗